2025 Half year results July 2025 Disclaimer This presentation contains certain statements that are, or may be deemed to be, "forward-looking statements" (including for purposes of the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements give Haleon's current expectations and projections about future events, including strategic initiatives and future financial condition ...

Core Insights - Aon plc reported second-quarter 2025 adjusted earnings of $3.49 per share, exceeding the Zacks Consensus Estimate by 2.7% and reflecting a 19.1% increase year-over-year [1][10] - Total revenues rose 11% year-over-year to $4.2 billion, surpassing the consensus mark by 0.7%, with organic revenue growth at 6% [1][10] Financial Performance - The strong quarterly results were driven by new business growth and solid retention rates, particularly in Aon's Risk Capital and Human Capital segments, aided by NFP acquisition synergies and net restructuring savings [2] - Total operating expenses increased 6% year-over-year to $3.3 billion, influenced by higher costs from the NFP acquisition and long-term growth investments [3] - Adjusted operating income advanced 14% year-over-year to $1.2 billion, with an adjusted operating margin of 28.2%, improving by 80 basis points year-over-year [4] Segmental Performance - **Risk Capital**: - Commercial Risk Solutions saw organic revenues grow 6% year-over-year, with revenues of $2.2 billion, an 8% increase [5] - Reinsurance Solutions experienced organic revenue growth of 6%, with revenues increasing 8% year-over-year to $688 million, surpassing the consensus estimate [6] - **Human Capital**: - Health Solutions reported organic revenue growth of 6%, with revenues climbing 17% year-over-year to $772 million, exceeding the consensus estimate [7] - Wealth Solutions saw organic revenues improve 3% year-over-year, with revenues growing 12% to $519 million, though it missed the consensus mark [8] Financial Position - As of June 30, 2025, Aon had cash and cash equivalents of $1 million, down from $1.1 billion at the end of 2024, while total assets increased to $54 billion from $49 billion [11] - Long-term debt decreased to $15.5 billion from $16.3 billion, with total short-term debt and current portion of long-term debt at $1.8 billion [11] - Cash flow from operations rose to $796 million from $513 million a year ago, with adjusted free cash flows increasing 59% year-over-year to $732 million [12] Capital Deployment - Aon repurchased 0.7 million class A ordinary shares for approximately $250 million in the second quarter, with a remaining repurchase capacity of around $1.8 billion [13] Forward Guidance - Aon expects mid-single-digit or higher organic revenue growth for 2025 and beyond, with anticipated expansion in adjusted operating margin and strong growth in adjusted EPS [14] - The Aon United Restructuring program is projected to achieve annual run-rate savings of approximately $350 million by the end of 2026 [15]

Core Insights - Aon plc reported strong financial results for the second quarter of 2025, with total revenue increasing by 11% to $4.2 billion and organic revenue growth of 6% [2][3][11] - The company experienced significant growth in adjusted earnings per share (EPS), which rose by 19% to $3.49, while diluted EPS increased by 8% to $2.66 [2][11][27] - Aon's performance is attributed to the successful execution of its Aon United strategy, which focuses on operational efficiency and meeting client demand in a complex environment [2][11] Financial Performance - Total revenue for the first half of 2025 reached $8.884 billion, a 13% increase from $7.830 billion in the prior year [2][3] - Operating income for the second quarter increased by 31% to $859 million, with an operating margin of 20.7%, up from 17.4% in the previous year [2][24] - Adjusted operating income rose by 14% to $1.171 billion, with an adjusted operating margin of 28.2% [2][24] Revenue Breakdown - Risk Capital revenue increased by 8% to $2.9 billion, while Human Capital revenue grew by 15% to $1.3 billion [3][11] - The growth in Risk Capital was driven by strong performance in Commercial Risk Solutions and Reinsurance Solutions, both achieving organic revenue growth of 6% [15][16] - Human Capital's Health Solutions segment saw a 6% organic revenue growth, supported by strong retention and new business [17] Expense Analysis - Total operating expenses for the second quarter rose by 6% to $3.3 billion, primarily due to the inclusion of NFP's operating expenses and increased amortization related to the NFP acquisition [4][19] - Compensation and benefits expenses increased by 11% to $2.36 billion, reflecting the integration of NFP and organic growth [19][36] - Amortization and impairment of intangible assets surged by 57% to $201 million, driven by the NFP acquisition [19][36] Cash Flow and Shareholder Returns - Cash provided by operations for the first half of 2025 increased by 14% to $936 million, while free cash flow rose by 13% to $816 million [8][9][41] - The company repurchased 0.7 million class A ordinary shares for approximately $250 million during the second quarter, with $1.8 billion remaining under its share repurchase program [7][11] Tax and Shareholder Metrics - The effective tax rate decreased to 15.5% from 22.9% in the prior year, contributing to improved net income [6][36] - Net income attributable to Aon shareholders increased by 10% to $579 million, with adjusted net income rising by 22% to $759 million [27][36]

Financial Data and Key Metrics Changes - In Q2 2025, total company operational sales grew 22% and organic sales grew 17%, exceeding the guidance range of 13% to 15% [6][23] - Adjusted EPS for Q2 was $0.75, representing a 23% increase, also surpassing the guidance range of $0.71 to $0.73 [6][23] - Adjusted operating margin was 27.6%, an increase of 50 basis points compared to Q2 2024 [7][24] Business Line Data and Key Metrics Changes - Urology sales grew 28% operationally and 6% organically, driven by stone management and prosthetic urology franchises [11] - Endoscopy grew 8% globally, with double-digit growth in the U.S., supported by strong performance in key products [12] - Cardiology sales increased by 28%, with interventional cardiology therapy sales growing 9% [13] Market Data and Key Metrics Changes - U.S. operational growth was 31%, primarily driven by the cardiovascular portfolio [8][9] - EMEA grew 2% operationally, with 7% growth excluding the Accurate Valve discontinuation [9] - Asia Pacific saw a 15% operational growth, led by strong performance in Japan, China, and Australia [10] Company Strategy and Development Direction - The company is focusing on expanding its portfolio and investing in clinical evidence to support new technologies [15][21] - There is a commitment to strategic acquisitions and high-growth adjacencies, with recent acquisitions of Sonae V and Entera Medical [26] - The company aims to continue outpacing market growth through organic portfolio enhancements and strategic M&A [94] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, expecting full-year organic growth to be in the range of 14% to 15% [28][29] - The anticipated impact of tariffs and the Accurate Valve discontinuation was discussed, with expectations for gross margin to remain flat for the year [24][45] - Management highlighted the importance of clinical data and reimbursement developments in driving future growth [72][75] Other Important Information - The company received a credit rating upgrade from Moody's to A3, reflecting improved financial stability [26] - Free cash flow for Q2 was $1,129 million, with expectations for full-year free cash flow to be approximately $3,500 million [26] Q&A Session Summary Question: WATCHMAN growth and durability - Management noted strong growth in WATCHMAN, driven by safety and efficacy, with expectations for continued growth in the future [35][38] Question: Gross margin concerns - Management addressed the impact of the Accurate Valve discontinuation on gross margin, emphasizing strong sales performance and cost controls [42][44] Question: Growth vectors for EP business - Management highlighted market growth, PFA adoption, and new product introductions as key growth drivers for the electrophysiology business [49][50] Question: MedSurg business performance - Management emphasized strong performance in Endoscopy and Neuromodulation, with expectations for continued growth despite some competitive pressures [55][60] Question: ASC setting and growth implications - Management expressed optimism about the ASC setting, viewing it as a positive development for future growth despite potential challenges [64][68] Question: Renal denervation market potential - Management discussed the potential of the renal denervation market, emphasizing the importance of clinical trials and market positioning [71][75] Question: Evolution of the EP portfolio - Management outlined plans for expanding the EP portfolio, including new product launches and indication expansions [78][82]

Financial Data and Key Metrics Changes - In Q2 2025, total company operational sales grew 22% and organic sales grew 17%, exceeding the guidance range of 13% to 15% [5][20] - Adjusted EPS for Q2 was $0.75, a 23% increase, surpassing the guidance range of $0.71 to $0.73 [5][20] - Adjusted operating margin was 27.6%, reflecting a 50 basis point increase compared to Q2 2024 [5][21] Business Line Data and Key Metrics Changes - Urology sales grew 28% operationally and 6% organically, driven by stone management and prosthetic urology franchises [9] - Endoscopy grew 8% globally, with double-digit growth in the U.S., supported by strong performance in key products [10] - Cardiology sales increased by 28%, with interventional cardiology therapy sales growing 9% [11] Market Data and Key Metrics Changes - U.S. operational growth was 31%, primarily from the cardiovascular portfolio [7] - EMEA grew 2% operationally, with 7% growth excluding the Accurate Valve discontinuation [7] - Asia Pacific saw a 15% operational growth, led by strong performance in Japan, China, and Australia [8] Company Strategy and Development Direction - The company is focused on expanding its portfolio and investing in clinical evidence to drive growth, particularly in the electrophysiology market [17][18] - Strategic acquisitions, such as Entera Medical, are aimed at enhancing the interventional oncology portfolio [19][23] - The company anticipates continued high single-digit growth in the second half of the year, driven by proprietary technologies and strategic partnerships [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving organic growth of 14% to 15% for the full year 2025, reflecting strong momentum across global businesses [6][24] - The anticipated impact of tariffs has been revised down to approximately $100 million for the full year [21][24] - Management highlighted the importance of clinical data and reimbursement decisions in shaping future growth, particularly in the WATCHMAN and FerriPulse markets [36][99] Other Important Information - The company received a credit rating upgrade from Moody's to A3, indicating improved financial stability [23] - Free cash flow for Q2 was $1.129 billion, with expectations of approximately $3.5 billion for the full year 2025 [23][24] Q&A Session Summary Question: WATCHMAN growth and durability - Management noted a 28% growth in WATCHMAN, driven by its safety and efficacy profile, and expects continued growth as more physicians adopt concomitant procedures [34][36] Question: Gross margin concerns - Management acknowledged a $130 million write-down related to the Accurate exit but emphasized strong sales performance and cost controls that offset this impact [40][43] Question: Growth vectors for electrophysiology business - Management highlighted market growth, PFA adoption, and new product launches as key growth drivers for the electrophysiology segment [48][50] Question: Capacity issues with WATCHMAN and FerriPulse - Management indicated no current capacity constraints but noted that hospitals are investing in additional labs to accommodate growing demand [102][106] Question: Impact of Medicare rule changes - Management expressed concerns about proposed reimbursement cuts but remains confident that physicians will prioritize appropriate treatments for patients [98][99]

Financial Data and Key Metrics Changes - For Q2 2025, the company achieved 8% adjusted and organic revenue growth and 16% adjusted EPS growth, with an adjusted operating margin of 39.6%, an increase of 120 basis points year-over-year [5][33] - Free cash flow for the quarter was $1,200,000,000, with expectations of approximately $5,500,000,000 for the full year [34][35] - The company refined its full-year organic revenue growth guidance to approximately 10%, at the low end of the previous range of 10% to 12% [7][46] Business Line Data and Key Metrics Changes - In the Merchant Solutions segment, organic revenue growth was 9% for both the quarter and year-to-date, with Clover revenue growing 30% in Q2 [35][39] - The Financial Solutions segment saw organic revenue growth of 7% in the quarter, driven by strong growth in issuing and digital payments [40][42] - Clover's volume growth was reported at 8%, with an adjusted growth of 11% excluding the gateway conversion [10][36] Market Data and Key Metrics Changes - The company reported a significant increase in Clover's value-added services (VAS) revenue, which grew 52% [11] - The international expansion of Clover is progressing well, particularly in Brazil, Mexico, and Canada, with new partnerships enhancing market penetration [12][13] Company Strategy and Development Direction - The company is focused on expanding its Clover platform through new products, markets, and partnerships, aiming to enhance its distribution channels and drive growth [9][20] - Strategic initiatives include the launch of Clover Hospitality and partnerships with TD Bank and Adobe to enhance service offerings [14][21] - The company is also investing in its digital payment solutions and cash flow management tools to meet evolving customer needs [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in capturing strategic and financial benefits from new product launches, despite some delays in execution [6][7] - The macroeconomic environment has been uncertain, impacting the timing of product rollouts and client implementations [78][79] - The company anticipates an acceleration in organic revenue growth in the second half of the year, particularly in the Merchant Solutions segment [46] Other Important Information - The company returned $2,200,000,000 to shareholders through share repurchases in the quarter, increasing its share repurchase guidance to approximately 130% of free cash flow [5][44] - Total debt outstanding was $29,600,000,000, with a debt to adjusted EBITDA ratio steady at 2.9 times [43][44] Q&A Session Summary Question: Insights on Clover Capital penetration - Management acknowledged that Clover Capital is underpenetrated compared to peers and discussed ongoing efforts to unlock total addressable market (TAM) through operational refinements and risk management strategies [49][52] Question: Changes in merchant growth rate expectations - Management clarified that the refinement in growth expectations is due to a combination of slower product rollouts and macroeconomic factors, not a decline in product quality [58][60] Question: Details on merchant operating margins - Management explained that the decline in merchant margins was anticipated due to acquisitions and investments in marketing and product development, which are expected to yield long-term benefits [85][88] Question: Acceleration in growth rates for the second half - Management indicated that the expected acceleration in growth rates is supported by easier year-over-year comparisons and continued expansion of Clover and Commerce Hub [91][94]

Q2 2025 Consolidated Gross Margin Analysis - The company's Q2 2025 reported gross margin (GAAP) was 62.4% compared to 61.07% in Q2 2024, representing an increase of 133 basis points[16] - The underlying gross margin expanded by approximately 160 basis points, driven by organic revenue growth, partially offset by higher commodity costs[5, 16] - Items impacting comparability primarily relate to economic hedging activities[5] - A structural tailwind of approximately 40 basis points was due to the impact from refranchising bottling operations in certain territories in India[4, 5] YTD 2025 Consolidated Gross Margin Analysis - The company's YTD 2025 reported gross margin (GAAP) was 62.49% compared to 61.77% in YTD 2024, representing an increase of 72 basis points[17] - The underlying gross margin expanded by approximately 120 basis points, driven by organic revenue growth, partially offset by higher commodity costs[7, 8] - The structural tailwind was due to the impact from refranchising bottling operations mainly in the Philippines and certain territories in India[8] Q2 2025 Consolidated Operating Margin Analysis - The company's Q2 2025 reported operating margin (GAAP) was 34.15% compared to 21.29% in Q2 2024, representing an increase of 1286 basis points[18] - The underlying operating margin expanded by approximately 320 basis points, primarily driven by organic revenue growth, the timing of marketing investments, and effective cost management[10, 11] - Items impacting comparability primarily relate to the remeasurement of the fairlife contingent consideration liability in the prior year, asset impairments, restructuring initiatives, and economic hedging activities[11] YTD 2025 Consolidated Operating Margin Analysis - The company's YTD 2025 reported operating margin (GAAP) was 33.55% compared to 20.17% in YTD 2024, representing an increase of 1338 basis points[19] - The underlying operating margin expanded by approximately 270 basis points, primarily driven by organic revenue growth, effective cost management, and the timing of marketing investments[13, 14] - The structural tailwind was due to the impact from refranchising bottling operations mainly in the Philippines and certain territories in India[14]

HNI Corporation Overview - HNI Corporation's TTM (Trailing Twelve Months) revenue is $2.53 billion[8] - HNI Corporation's TTM Non-GAAP EBITDA is $322.7 million[8] - HNI Corporation's 2024 Cash Dividends totaled $63.6 million[8] - HNI Corporation's five-year average free cash flow is $137 million, exceeding $3.00 per share[8] Workplace Furnishings Segment - HNI expects total savings of $80-$85 million compared to 2022, with $45-$50 million benefiting 2025 and 2026, equating to $0.70-$0.80 of incremental EPS[6,34] - HNI anticipates KII (Kimball International) synergies to reach $60 million by the end of 2026, more than double the initial projection from mid-2023[6,34] - HNI expects total net savings from the Mexico facility ramp to reach $20-$25 million by the end of 2026[6,34] - HNI expects total savings of $11 million by the end of 2026 from Hickory consolidation, which are included in KII synergies[6,34] - Industry shipments remain 12% below pre-COVID levels[57,58] - 2024 industry volume (adjusted for pricing actions/inflation) is approximately 35% below 2019 levels[57,58] Residential Building Products Segment - Approximately 20-25% of HNI's new home business flows through its vertically-integrated installing distribution model[67] - 61% of all mortgage rates are below 4%, creating a "lock-in" effect that is positive for future remodel/retrofit activity[75]

Core Insights - Steelcase Inc. reported first quarter revenue of $779.0 million, a 7% increase from $727.3 million in the prior year, with net income rising to $13.6 million from $10.9 million [1][23][38] - The company experienced organic revenue growth of 7%, driven by a 9% increase in the Americas, while international revenue saw a 1% decline [1][16] - The backlog at the end of the first quarter was approximately $801 million, a 2% increase compared to the previous year [11] Financial Performance - Adjusted earnings per share for the first quarter were $0.20, up from $0.16 in the prior year [18] - Operating income increased by 45% to $25.5 million, with adjusted operating income rising to $39.0 million, an increase of $10.8 million [3][4][23] - Gross margin improved to 33.9%, reflecting a 170 basis point increase from the previous year [4][6] Revenue Breakdown - Revenue from the Americas segment was $603.6 million, a 9% increase, while international revenue was $175.4 million, a 1% increase [14][25] - The Americas accounted for 77.5% of total revenue, while international revenue made up 22.5% [14] Orders and Market Dynamics - Orders adjusted for currency translation effects declined modestly, with a 1% decrease in the Americas and a 1% increase in international orders [2] - The decline in the Americas was attributed to decreases from government and education customers, despite growth from large corporate clients [2][3] Strategic Initiatives - The company initiated restructuring actions in the Americas aimed at reducing annualized spending by approximately $20 million [6] - Steelcase is focusing on investments in strategic initiatives and growth areas, particularly in response to weak demand in Germany and France [6] Outlook - For the second quarter of fiscal 2026, Steelcase expects revenue in the range of $860 to $890 million, translating to flat to 4% growth compared to the prior year [11][20] - Projected adjusted earnings per share for the second quarter are estimated to be between $0.36 to $0.40 [22]

Core Insights - The Coca-Cola Company (KO) has demonstrated strong growth, reflecting its robust market positioning and brand power compared to other non-alcoholic beverage companies [1] - Concerns arise regarding KO's current forward 12-month price-to-earnings (P/E) multiple of 23.37X, which is significantly higher than the industry average of 18.68X, suggesting the stock may be overvalued [2][5] - The price-to-sales (P/S) ratio of 6.27X also exceeds the industry's 4.46X, contributing to investor unease, particularly given its Value Score of F [3] Valuation Concerns - KO's premium valuation at 23.37X P/E is significantly above peers like PepsiCo (16.13X), Keurig Dr Pepper (15.7X), and Primo Brands (18.13X), indicating a potential disconnect between valuation and growth trajectory [5][6] - Despite a year-to-date share price increase of 15.3%, which outperformed the broader industry and major indexes, the high valuation raises questions about sustainability [7][8] Financial Performance - Coca-Cola reported a 12% organic revenue growth, driven by strong pricing and recovery in away-from-home consumption, showcasing resilience amid macroeconomic uncertainties [14] - The company has outperformed competitors like PepsiCo and Keurig Dr Pepper, which saw declines of 21.3% and 2.6% respectively, while KO's performance is still below Primo Brands' growth of 29.5% [8] Market Positioning - KO's current share price of $71.77 is 3.5% below its 52-week high of $74.38 and 18.4% above its 52-week low of $60.62, indicating a bullish sentiment as it trades above its 50 and 200-day moving averages [12] - The company's disciplined brand-building strategy and marketing investments have resonated well, particularly with products like Coca-Cola Zero Sugar, which has seen double-digit growth [16] Strategic Outlook - Coca-Cola's ability to innovate and engage with younger, health-conscious consumers is crucial for maintaining its market leadership [17] - The company is focused on margin resilience through productivity initiatives and pricing power, despite facing inflationary pressures and currency fluctuations [18] - Management's confidence is reflected in the full-year guidance, indicating a strong belief in the underlying business fundamentals [15] Earnings Estimates - The Zacks Consensus Estimate for Coca-Cola's 2025 EPS remains unchanged, while the estimate for 2026 EPS has seen a slight upward revision, indicating analysts' confidence in the stock [20] - For 2025, the consensus estimates imply 2.4% revenue growth and 2.8% EPS growth, with 2026 estimates suggesting 5.3% revenue growth and 8.2% EPS growth [20] Investment Considerations - Despite premium valuation concerns, Coca-Cola's strong fundamentals, brand equity, and strategic direction present a compelling case for long-term investors [23][24] - The company's global scale and disciplined execution support its growth trajectory across diverse markets, making it a potential addition to a diversified portfolio [25][26]